Cover Image
市場調查報告書

惡性胸水:開發中產品分析

Malignant Pleural Effusion - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 484633
出版日期 內容資訊 英文 32 Pages
訂單完成後即時交付
價格
Back to Top
惡性胸水:開發中產品分析 Malignant Pleural Effusion - Pipeline Review, H2 2017
出版日期: 2017年09月12日 內容資訊: 英文 32 Pages
簡介

惡性胸水是由於癌症造成浴著肺部外側並排的組織(肋膜)薄層和胸腔臂間聚集異常大量的液體之狀態。大部分肺癌,乳癌,淋巴瘤及白血病都會發生惡性胸水。

本報告提供全球各國治療惡性胸水所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

惡性胸水;概要

惡性胸水 - 治療藥的開發

  • 開發中產品 概要
  • 開發中產品:各企業
  • 企業開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Advantagene Inc
  • Biogen Inc
  • Genelux Corp
  • Shenzen SiBiono GeneTech Co Ltd

藥物簡介

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9703IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Pleural Effusion - Pipeline Review, H2 2017, provides an overview of the Malignant Pleural Effusion (Respiratory) pipeline landscape.

Malignant pleural effusion is a condition in which cancer causes an abnormal amount of fluid to collect between the thin layers of tissue (pleura) lining the outside of the lung and the wall of the chest cavity. Lung cancer, breast cancer, lymphoma, and leukemia cause most malignant pleural effusions.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malignant Pleural Effusion - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Malignant Pleural Effusion (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malignant Pleural Effusion (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Malignant Pleural Effusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 3 and 1 respectively.

Malignant Pleural Effusion (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Pleural Effusion (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Malignant Pleural Effusion (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Malignant Pleural Effusion (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Malignant Pleural Effusion (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Pleural Effusion (Respiratory)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Malignant Pleural Effusion (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Malignant Pleural Effusion (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Malignant Pleural Effusion - Overview
    • Malignant Pleural Effusion - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Malignant Pleural Effusion - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Malignant Pleural Effusion - Companies Involved in Therapeutics Development
    • Advantagene Inc
    • Biogen Inc
    • Genelux Corp
  • Malignant Pleural Effusion - Drug Profiles
    • BG-00001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Malignant Pleural Effusion - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Malignant Pleural Effusion and Solid Tumors - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate p53 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GLONC-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • methotrexate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Malignant Pleural Effusion - Dormant Projects
  • Malignant Pleural Effusion - Product Development Milestones
    • Featured News & Press Releases
      • May 12, 2015: Genelux to Present Posters Supporting Lead Oncolytic Viral Therapy GL-ONC1 at ASCO Annual Meeting 2015
      • Jun 15, 2013: Genelux Presents Abstracts at the 7th International Meeting on Replicating Oncolytic Virus Therapeutics in Quebec
      • May 30, 2013: Genelux To Present Abstracts For Clinical Trials Of Oncolytic Viral Therapy GL-ONC1 At 2013 ASCO Annual Meeting
      • Feb 06, 2013: Genelux Announces Treatment Of First Patient In Phase I Trial With GL-ONC1 At Memorial Sloan Kettering Cancer Center
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Malignant Pleural Effusion, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Malignant Pleural Effusion - Pipeline by Advantagene Inc, H2 2017
  • Malignant Pleural Effusion - Pipeline by Biogen Inc, H2 2017
  • Malignant Pleural Effusion - Pipeline by Genelux Corp, H2 2017
  • Malignant Pleural Effusion - Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development for Malignant Pleural Effusion, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top